Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

SML3743

Sigma-Aldrich

Tegobuvir

≥98% (HPLC)

Sinonimo/i:

GS 9190, 5-({6-[2,4-Bis(trifluoromethyl)phenyl]pyridazin-3-yl}methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine, 5-[[6-[2,4-Bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine, GS 333126, GS-333126, GS-9190, GS333126, GS9190, TGV

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C25H14F7N5
Numero CAS:
Peso molecolare:
517.40
Numero MDL:
Codice UNSPSC:
51111800
Codice UNSPSC:
12352200
NACRES:
NA.77

Livello qualitativo

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to beige

Solubilità

DMSO: 2 mg/mL, clear

Temperatura di conservazione

-10 to -25°C

Stringa SMILE

FC(F)(F)c1c(ccc(c1)C(F)(F)F)c2nnc(cc2)C[n]3cc4nc(nc4cc3)c5c(cccc5)F

InChI

1S/C25H14F7N5/c26-19-4-2-1-3-17(19)23-33-21-9-10-37(13-22(21)34-23)12-15-6-8-20(36-35-15)16-7-5-14(24(27,28)29)11-18(16)25(30,31)32/h1-11,13H,12H2
XBEQSQDCBSKCHJ-UHFFFAOYSA-N

Azioni biochim/fisiol

Orally active, non-cytotoxic, potent and genotype 1 replicons-selective non-nucleoside inhibitor (NNI) against hepatitis C virus (HCV).
Tegobuvir (GS-9190; TGV) is an orally active, non-cytotoxic imidazopyridine that, upon CYP-mediated intracellular activation, forms a glutathione conjugate that acts as a covalent, potent and genotype 1 replicons-selective non-nucleoside inhibitor (NNI) against hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (IC50 = 0.8 nM/1b, 13.8 nM/1a, 21.9 μM/2a, >50 μM/1a; IC50 >100 nM against 2b, 3a, 4a, 5a, and 6a). When combined with suboptimal concentrations of other direct acting antivirals (DAAs) in cultures, tegobuvir (6-30 nM) is highly effective in curing cells from HCV replicon and in delaying or preventing the development of resistance against other DAAs.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Christy M Hebner et al.
PloS one, 7(6), e39163-e39163 (2012-06-22)
Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the identification of resistance
Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a.
Virology, 429(1), 57-62 (2012)
Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase
Antimicrobial Agents and Chemotherapy, 55(9), 4196-4203 (2011)
Inge Vliegen et al.
Antiviral research, 120, 112-121 (2015-06-04)
Tegobuvir (GS-9190) is a non-nucleoside inhibitor of HCV RNA replication with proven antiviral activity in HCV-infected patients. The in vitro antiviral activity of Tegobuvir, when combined with one or two other direct acting antivirals (DAA) was assessed. When Tegobuvir was

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.